\-\ Texto\\:\\ \ \(0\)\
\-\ urine\\ oxalate\\ of\\ 130\\ mg\\/day\ \(1\)\
\-\ improving\\ post\\ liver\\ transplant\ \(0\)\
\-\ \\â\\€\\¢\\ radiographs\\ of\\ the\\ spine\\ demonstrate\\ diffusely\\ increased\\ density\ \(0\)\
\-\ \\â\\€\\¢\\ the\\ kidneys\\ also\\ appear\\ hyperdense\\ \\(no\\ recent\\ iv\\ contrast\\ administration\\)\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ surgical\\ staples\\ consistent\\ with\\ recent\\ liver\\ transplant\\.\ \(0\)\
\-\ renal\\ oxalosis\ \(0\)\
\-\ \\â\\€\\¢\\ hyperdense\\ bones\\ \\(courtesy\\ dr\\.\\ clyde\\ helms\\)\\:\ \(0\)\
\-\ renal\\ osteodystrophy\\ \ \(4\)\
\-\ sickle\\ cell\\ disease\\ \ \(17\)\
\-\ myelofibrosis\\ \ \(1\)\
\-\ osteopetrosis\\ \ \(0\)\
\-\ pyknodysostosis\\ \ \(1\)\
\-\ mastocytosis\\ \ \(0\)\
\-\ metastases\\ \\-\\ breast\\ and\\ prostate\\ \ \(0\)\
\-\ paget\\ disease\\ \ \(0\)\
\-\ athletes\\ \ \(4\)\
\-\ fluorosis\ \(0\)\
\-\ 23\\ yo\\ man\\ who\\ has\\ a\\ history\\ of\\ recurrent\\ calcium\\ oxalate\\ nephrolithiasis\\ treated\\ with\\ pyridoxine\\.\\ \\ he\\ also\\ has\\ a\\ cardiac\\ arrythmia\\ and\\ recently\\ underwent\\ a\\ liver\\ transplant\\.\ \(0\)\
\-\ the\\ images\\ reveal\\ severe\\ cortical\\ nephrocalcinosis\\,\\ osteosclerosis\\,\\ and\\ renal\\ osteodystrophy\\.\\ \\ the\\ differential\\ diagnosis\\ for\\ cortical\\ nephrocalcinosis\\ includes\\ renal\\ cortical\\ necrosis\\,\\ chronic\\ or\\ hereditary\\ glomerulonephritis\\,\\ and\\ oxalosis\\,\\ and\\ renal\\ transplant\\ rejection\\.\\ \\ consider\\ why\\ this\\ young\\ patient\\ has\\ cortical\\ nephrocalcinosis\\ and\\ has\\ had\\ a\\ liver\\ transplant\\.\ \(0\)\
\-\ the\\ patient\\ clinically\\ has\\ primary\\ hyperoxaluria\\ \\(\\ urine\\ oxalate\\ \\>\\ 80\\ mg\\ \\/\\ day\\)\\.\\ \\ primary\\ hyperoxaluria\\ is\\ usually\\ divided\\ into\\ two\\ autosomal\\ recessive\\ diseases\\:\\ type\\ 1\\ \\(peroxisomal\\ liver\\ agt\\ enzyme\\ disorder\\)\\ and\\ type\\ 2\\ \\(cytosolic\\ enzyme\\ disorder\\)\\.\\ \\ usually\\ type\\ 2\\ hyperoxaluria\\ has\\ a\\ mild\\ clinical\\ course\\ \\(unlike\\ this\\ case\\)\\.\ \(0\)\
\-\ this\\ patient\\ has\\ type\\ 1\\ primary\\ hyperoxaluria\\ \\(ph1\\)\\ and\\ \\"oxalosis\\.\\"\\ \\ oxalosis\\ refers\\ to\\ calcium\\ oxalate\\ deposition\\ in\\ tissues\\ other\\ than\\ the\\ kidney\\ which\\ occurs\\ when\\ oxalateretention\\ due\\ to\\ renal\\ failure\\ is\\ added\\ to\\ oxalate\\ over\\-production\\ due\\ to\\ a\\ metabolic\\ condition\\.\ \(0\)\
\-\ ph1\\ is\\ caused\\ by\\ a\\ rare\\ inborn\\ error\\ in\\ liver\\ metabolism\\ \\(autosomal\\ recessive\\)\\ in\\ which\\ excessive\\ amounts\\ of\\ oxalic\\ acid\\ are\\ formed\\ which\\ combine\\ with\\ calcium\\ and\\ deposit\\ throughout\\ the\\ body\\ \\(kidney\\,\\ soft\\ tissue\\,\\ bone\\)\\.\\ \\ the\\ hepatic\\ peroxisomal\\ enzyme\\ agt\\ \\(alanine\\:glyoxylate\\ aminotransferase\\)\\ is\\ defective\\ and\\ glyoxylate\\ cannot\\ be\\ converted\\ into\\ glycine\\;\\ hence\\,\\ excessive\\ glyoxylate\\ is\\ metabolized\\ into\\ oxalate\\.\ \(0\)\
\-\ this\\ disorder\\ leads\\ to\\ progressive\\ renal\\ failure\\ secondary\\ to\\ cortical\\ nephrocalcinosis\\ which\\ usually\\ leads\\ to\\ early\\ death\\ in\\ childhood\\ unless\\ dialysis\\ is\\ instituted\\.\\ \\ common\\ radiographic\\ findings\\ in\\ oxalosis\\ include\\ dense\\ kidneys\\ \\(nephrocalcinosis\\)\\,\\ dense\\ bones\\ \\(calcium\\ oxalate\\ crystal\\ deposition\\ and\\ renal\\ osteodystrophy\\)\\,\\ soft\\ tissue\\ and\\ vascular\\ calcifications\\,\\ and\\ radiopaque\\ renal\\ calculi\\.\\ \\ treatment\\ includes\\ pyridoxine\\,\\ dialysis\\,\\ and\\ liver\\ transplant\\ to\\ replace\\ the\\ defective\\ agt\\ enzyme\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ oxalate\\:\\ 0\\.3696012560923641\ \(0\)\
\-\ oxalosis\\:\\ 0\\.2868066786633233\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.22785458880382006\ \(0\)\
\-\ transplant\\:\\ 0\\.22523746498065733\ \(0\)\
\-\ hyperoxaluria\\:\\ 0\\.22187313932748096\ \(0\)\
\-\ renal\\:\\ 0\\.21037677565607002\ \(0\)\
\-\ enzyme\\:\\ 0\\.20052829620664947\ \(0\)\
\-\ liver\\:\\ 0\\.18126211397262745\ \(0\)\
\-\ glyoxylate\\:\\ 0\\.18008832336830577\ \(0\)\
\-\ agt\\:\\ 0\\.172084007197994\ \(0\)\
\-\ calcium\\:\\ 0\\.1356140028306891\ \(0\)\
\-\ cortical\\:\\ 0\\.13474450279883546\ \(0\)\
\-\ osteodystrophy\\:\\ 0\\.13022773061894607\ \(0\)\
\-\ ph1\\:\\ 0\\.1200588822455372\ \(0\)\
\-\ has\\:\\ 0\\.12001986788893909\ \(0\)\
\-\ pyridoxine\\:\\ 0\\.11472267146532933\ \(0\)\
\-\ peroxisomal\\:\\ 0\\.11472267146532933\ \(0\)\
\-\ defective\\:\\ 0\\.11093656966374048\ \(0\)\
\-\ and\\:\\ 0\\.10859114860653811\ \(0\)\
\-\ type\\:\\ 0\\.1007243594716549\ \(0\)\
\-\ disorder\\:\\ 0\\.09525529981682893\ \(0\)\
\-\ recessive\\:\\ 0\\.08735573371993917\ \(0\)\
\-\ dialysis\\:\\ 0\\.08316465488476893\ \(0\)\
\-\ excessive\\:\\ 0\\.08096610366635054\ \(0\)\
\-\ autosomal\\:\\ 0\\.07743555776096481\ \(0\)\
\-\ deposition\\:\\ 0\\.07574286109155562\ \(0\)\
\-\ leads\\:\\ 0\\.07574286109155562\ \(0\)\
\-\ to\\:\\ 0\\.07507291775909694\ \(0\)\
\-\ usually\\:\\ 0\\.07089233185791838\ \(0\)\
\-\ primary\\:\\ 0\\.0692431624043149\ \(0\)\
\-\ hyperdense\\:\\ 0\\.06911110855634575\ \(0\)\
\-\ which\\:\\ 0\\.06827334172842696\ \(0\)\
\-\ the\\:\\ 0\\.06740948265875638\ \(0\)\
\-\ urine\\:\\ 0\\.06720040948376911\ \(0\)\
\-\ dense\\:\\ 0\\.06617437984592091\ \(0\)\
\-\ mg\\:\\ 0\\.065532266394473\ \(0\)\
\-\ kidneys\\:\\ 0\\.06462427086730188\ \(0\)\
\-\ is\\:\\ 0\\.06167817034066681\ \(0\)\
\-\ bones\\:\\ 0\\.06040663154859955\ \(0\)\
\-\ cytosolic\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ oxalateretention\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ oxalic\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ alanine\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ glycine\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ metabolized\\:\\ 0\\.0600294411227686\ \(0\)\
\-\ into\\:\\ 0\\.05986167641127189\ \(0\)\
\-\ includes\\:\\ 0\\.05837789836534584\ \(0\)\
\-\ inborn\\:\\ 0\\.057361335732664664\ \(0\)\
\-\ aminotransferase\\:\\ 0\\.057361335732664664\ \(0\)\
\-\ failure\\:\\ 0\\.05699734487707827\ \(0\)\
\-\ staples\\:\\ 0\\.05546828483187024\ \(0\)\
\-\ clyde\\:\\ 0\\.05546828483187024\ \(0\)\
\-\ arrythmia\\:\\ 0\\.053999920476657824\ \(0\)\
\-\ combine\\:\\ 0\\.053999920476657824\ \(0\)\
\-\ rejection\\:\\ 0\\.05280017944176631\ \(0\)\
\-\ kidney\\:\\ 0\\.052741886121764524\ \(0\)\
\-\ courtesy\\:\\ 0\\.051785812850139445\ \(0\)\
\-\ osteosclerosis\\:\\ 0\\.051785812850139445\ \(0\)\
\-\ error\\:\\ 0\\.051785812850139445\ \(0\)\
\-\ this\\:\\ 0\\.051593218367477225\ \(0\)\
\-\ converted\\:\\ 0\\.05090712854097188\ \(0\)\
\-\ replace\\:\\ 0\\.05090712854097188\ \(0\)\
\-\ recent\\:\\ 0\\.05083225524570024\ \(0\)\
\-\ deposit\\:\\ 0\\.04881158912338676\ \(0\)\
\-\ instituted\\:\\ 0\\.04823902315086794\ \(0\)\
\-\ day\\:\\ 0\\.04782053650261969\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.04771231351417757\ \(0\)\
\-\ in\\:\\ 0\\.04668963063335502\ \(0\)\
\-\ why\\:\\ 0\\.04557091776076401\ \(0\)\
\-\ added\\:\\ 0\\.04557091776076401\ \(0\)\
\-\ amounts\\:\\ 0\\.04557091776076401\ \(0\)\
\-\ helms\\:\\ 0\\.04521513611244352\ \(0\)\
\-\ refers\\:\\ 0\\.04521513611244352\ \(0\)\
\-\ radiopaque\\:\\ 0\\.04521513611244352\ \(0\)\
\-\ 130\\:\\ 0\\.04487760789486111\ \(0\)\
\-\ crystal\\:\\ 0\\.044250432832488404\ \(0\)\
\-\ improving\\:\\ 0\\.04395792434052903\ \(0\)\
\-\ calculi\\:\\ 0\\.04395792434052903\ \(0\)\
\-\ dr\\:\\ 0\\.043677866859969584\ \(0\)\
\-\ due\\:\\ 0\\.0431536588632385\ \(0\)\
\-\ hence\\:\\ 0\\.04315115722327921\ \(0\)\
\-\ metabolism\\:\\ 0\\.04290281237066008\ \(0\)\
\-\ divided\\:\\ 0\\.041784815959175166\ \(0\)\
\-\ unlike\\:\\ 0\\.041784815959175166\ \(0\)\
\-\ formed\\:\\ 0\\.04082946642288685\ \(0\)\
\-\ soft\\:\\ 0\\.03996753790746838\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.03939676804963067\ \(0\)\
\-\ tissue\\:\\ 0\\.039381869966946405\ \(0\)\
\-\ acid\\:\\ 0\\.038981028286611936\ \(0\)\
\-\ hereditary\\:\\ 0\\.03859000093238085\ \(0\)\
\-\ childhood\\:\\ 0\\.03798587443144123\ \(0\)\
\-\ consider\\:\\ 0\\.03692221654145996\ \(0\)\
\-\ unless\\:\\ 0\\.03692221654145996\ \(0\)\
\-\ death\\:\\ 0\\.03682472797968798\ \(0\)\
\-\ patient\\:\\ 0\\.036626464883477115\ \(0\)\
\-\ prostate\\:\\ 0\\.03635784018737421\ \(0\)\
\-\ also\\:\\ 0\\.03531242643303516\ \(0\)\
\-\ diffusely\\:\\ 0\\.03490752895065006\ \(0\)\
\-\ diseases\\:\\ 0\\.03448736343414428\ \(0\)\
\-\ metabolic\\:\\ 0\\.034028844641482495\ \(0\)\
\-\ recently\\:\\ 0\\.0327661331972365\ \(0\)\
\-\ reveal\\:\\ 0\\.03157510210082589\ \(0\)\
\-\ disease\\:\\ 0\\.031513191494817905\ \(0\)\
\-\ clinically\\:\\ 0\\.031194139022166036\ \(0\)\
\-\ 23\\:\\ 0\\.03095188991575548\ \(0\)\
\-\ young\\:\\ 0\\.03095188991575548\ \(0\)\
\-\ recurrent\\:\\ 0\\.030098027807132565\ \(0\)\
\-\ caused\\:\\ 0\\.030098027807132565\ \(0\)\
\-\ condition\\:\\ 0\\.02999439798727451\ \(0\)\
\-\ administration\\:\\ 0\\.029892374896166137\ \(0\)\
\-\ hepatic\\:\\ 0\\.029892374896166137\ \(0\)\
\-\ tissues\\:\\ 0\\.029595466298685685\ \(0\)\
\-\ occurs\\:\\ 0\\.029595466298685685\ \(0\)\
\-\ appear\\:\\ 0\\.029563288446978947\ \(0\)\
\-\ of\\:\\ 0\\.029383106302832456\ \(0\)\
\-\ 80\\:\\ 0\\.029280556567861417\ \(0\)\
\-\ progressive\\:\\ 0\\.028749117963981097\ \(0\)\
\-\ necrosis\\:\\ 0\\.028692633861274623\ \(0\)\
\-\ rare\\:\\ 0\\.02833685221295414\ \(0\)\
\-\ cardiac\\:\\ 0\\.027873980061561505\ \(0\)\
\-\ radiographic\\:\\ 0\\.027849195258017656\ \(0\)\
\-\ course\\:\\ 0\\.02772665246971761\ \(0\)\
\-\ throughout\\:\\ 0\\.027606350077730022\ \(0\)\
\-\ calcifications\\:\\ 0\\.027395197494432103\ \(0\)\
\-\ breast\\:\\ 0\\.027258101753141986\ \(0\)\
\-\ early\\:\\ 0\\.02705766927684968\ \(0\)\
\-\ iv\\:\\ 0\\.026820707721998523\ \(0\)\
\-\ underwent\\:\\ 0\\.025857928241958164\ \(0\)\
\-\ density\\:\\ 0\\.024890732874277132\ \(0\)\
\-\ spine\\:\\ 0\\.024796726167479025\ \(0\)\
\-\ vascular\\:\\ 0\\.024781188125875566\ \(0\)\
\-\ body\\:\\ 0\\.024704043542895078\ \(0\)\
\-\ differential\\:\\ 0\\.024389563886745746\ \(0\)\
\-\ radiographs\\:\\ 0\\.024345840419823593\ \(0\)\
\-\ clinical\\:\\ 0\\.023789029984493906\ \(0\)\
\-\ severe\\:\\ 0\\.023762388824373037\ \(0\)\
\-\ yo\\:\\ 0\\.02345083442168891\ \(0\)\
\-\ treated\\:\\ 0\\.023375197295118888\ \(0\)\
\-\ when\\:\\ 0\\.022674371314679143\ \(0\)\
\-\ include\\:\\ 0\\.02233402676597665\ \(0\)\
\-\ two\\:\\ 0\\.022291366275805306\ \(0\)\
\-\ chronic\\:\\ 0\\.02228074422739458\ \(0\)\
\-\ secondary\\:\\ 0\\.022248980573306255\ \(0\)\
\-\ he\\:\\ 0\\.022227889665630433\ \(0\)\
\-\ with\\:\\ 0\\.02205049702638509\ \(0\)\
\-\ cell\\:\\ 0\\.021472752591784695\ \(0\)\
\-\ common\\:\\ 0\\.021287638906482526\ \(0\)\
\-\ mild\\:\\ 0\\.021278518520321744\ \(0\)\
\-\ than\\:\\ 0\\.021278518520321744\ \(0\)\
\-\ who\\:\\ 0\\.021233105244412305\ \(0\)\
\-\ bone\\:\\ 0\\.02048122282588487\ \(0\)\
\-\ post\\:\\ 0\\.020424945753572527\ \(0\)\
\-\ consistent\\:\\ 0\\.02035328960926214\ \(0\)\
\-\ increased\\:\\ 0\\.020298091558902914\ \(0\)\
\-\ man\\:\\ 0\\.019872423529604926\ \(0\)\
\-\ demonstrate\\:\\ 0\\.019514317898367262\ \(0\)\
\-\ other\\:\\ 0\\.019493438903923403\ \(0\)\
\-\ diagnosis\\:\\ 0\\.01945878712526211\ \(0\)\
\-\ case\\:\\ 0\\.01885805693797807\ \(0\)\
\-\ had\\:\\ 0\\.018702190874034755\ \(0\)\
\-\ findings\\:\\ 0\\.01852589361427588\ \(0\)\
\-\ surgical\\:\\ 0\\.018244086802945213\ \(0\)\
\-\ contrast\\:\\ 0\\.01823834227393648\ \(0\)\
\-\ treatment\\:\\ 0\\.017880747605199074\ \(0\)\
\-\ images\\:\\ 0\\.017363247707676988\ \(0\)\
\-\ by\\:\\ 0\\.015940282703150174\ \(0\)\
\-\ be\\:\\ 0\\.01522716038438553\ \(0\)\
\-\ history\\:\\ 0\\.014341212986664267\ \(0\)\
\-\ are\\:\\ 0\\.014243490910782402\ \(0\)\
\-\ or\\:\\ 0\\.013058368257952112\ \(0\)\
\-\ no\\:\\ 0\\.012206525219649687\ \(0\)\
\-\ for\\:\\ 0\\.01137710199828058\ \(0\)\
\-\ can\\:\\ 0\\.0\ \(0\)\
\-\ not\\:\\ 0\\.0\ \(0\)\
